Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Junb regulates arterial contraction capacity, cellular contractility, and motility via its target Myl9 in mice
Alexander H. Licht, … , Thomas Korff, Marina Schorpp-Kistner
Alexander H. Licht, … , Thomas Korff, Marina Schorpp-Kistner
Published June 14, 2010
Citation Information: J Clin Invest. 2010;120(7):2307-2318. https://doi.org/10.1172/JCI41749.
View: Text | PDF
Research Article Vascular biology

Junb regulates arterial contraction capacity, cellular contractility, and motility via its target Myl9 in mice

  • Text
  • PDF
Abstract

Cellular contractility and, thus, the ability to alter cell shape are prerequisites for a number of important biological processes such as cytokinesis, movement, differentiation, and substrate adherence. The contractile capacity of vascular smooth muscle cells (VSMCs) is pivotal for the regulation of vascular tone and thus blood pressure and flow. Here, we report that conditional ablation of the transcriptional regulator Junb results in impaired arterial contractility in vivo and in vitro. This was exemplified by resistance of Junb-deficient mice to DOCA-salt–induced volume-dependent hypertension as well as by a decreased contractile capacity of isolated arteries. Detailed analyses of Junb-deficient VSMCs, mouse embryonic fibroblasts, and endothelial cells revealed a general failure in stress fiber formation and impaired cellular motility. Concomitantly, we identified myosin regulatory light chain 9 (Myl9), which is critically involved in actomyosin contractility and stress fiber assembly, as a Junb target. Consistent with these findings, reexpression of either Junb or Myl9 in Junb-deficient cells restored stress fiber formation, cellular motility, and contractile capacity. Our data establish a molecular link between the activator protein–1 transcription factor subunit Junb and actomyosin-based cellular motility as well as cellular and vascular contractility by governing Myl9 transcription.

Authors

Alexander H. Licht, Tobias Nübel, Anja Feldner, Nathalie Jurisch-Yaksi, Marco Marcello, Elena Demicheva, Jun-Hao Hu, Bettina Hartenstein, Hellmut G. Augustin, Markus Hecker, Peter Angel, Thomas Korff, Marina Schorpp-Kistner

×

Figure 1

Conditional Junb-deficient mice do not develop hypertension and adaptive responses in the DOCA-salt model.

Options: View larger image (or click on image) Download as PowerPoint
Conditional Junb-deficient mice do not develop hypertension and adaptive...
(A and B) Relative increase in systolic blood pressure (A) and in heart weight (B) is depicted for wild-type control (co) and Junb-deficient (Δ/–) mice subjected to sham operation or DOCA-salt treatment for 21 days. (C) Left: Whole-mount double-staining of retinal vessels with FITC-coupled lectin (green) and α-SMA antibody (red). Arrows indicate veins; arrowheads, strongly α-SMA–positive arteries. Right: Complete deletion of the Junb locus was verified by PCR with genomic DNA preparations from complete retinas of wild-type and Junb-deficient mice. Col1α2-iCre (Cre) PCR served as control for equal quality and loading. (D) Relative arteriolar narrowing determined by comparing diameters of arterioles from untreated and DOCA-salt–treated control and JunbΔ/– mice within a distance of 250 μm from the optical disc. (E) Ratio of artery to vein diameters is plotted for untreated and DOCA-salt–treated control and JunbΔ/– mice. (F) Immunofluorescence costaining of femoral arteries isolated from untreated or DOCA-salt–treated control and JunbΔ/– mice for CD31 and desmin, PCNA, or calponin. Scale bars in C and F: 50 μm. In each case, one representative staining of sections or of retinas of at least 3 different mice is shown. Data in A, B, D, and E represent mean ± SEM (n ≥ 6 for each condition). *P < 0.05, **P < 0.01, ***P = 0.005.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts